Nanocurie to Gigabecquerel

Receptor binding assays are the classic example. A biochemist adds 2–5 nCi of tritium-labelled drug to a plate of cells and measures how much binds to a receptor versus washing away. Metabolic tracing studies use similar amounts of carbon-14-labelled glucose or amino acids to follow biochemical pathways. At nanocurie levels the radioactivity is low enough that bench work requires minimal shielding — a few centimeters of acrylic for tritium beta particles — but high enough to produce a detectable signal after hours of counting.

One nanocurie equals 37 Bq — about the activity of 2.5 bananas worth of potassium-40, or roughly 0.5% of the natural K-40 activity in your own body. A smoke detector contains about 30,000 nCi (1 µCi) of americium. The nanocurie sits in the gap between environmental levels you cannot avoid (picocuries) and laboratory quantities that require formal licensing (microcuries). It is the unit of "detectable but not dangerous," which is exactly why it suits low-level lab work.

Tritium (hydrogen-3) is the perfect biological tracer because hydrogen appears in every organic molecule. You can replace a hydrogen atom with tritium without changing the molecule's chemistry — the drug, amino acid, or sugar behaves identically in the cell. Tritium emits only very low-energy beta particles (max 18.6 keV) that cannot penetrate skin or even a lab bench surface, making it the safest radioisotope to handle. The downside is low specific activity, so you need sensitive liquid scintillation counting to detect it — but at nanocurie levels, that is perfectly adequate.

In the US, NRC exempt quantities vary by isotope. For tritium, the exempt quantity is 1,000 µCi (1 mCi); for carbon-14 it is 100 µCi; for iodine-125 it is just 1 µCi. Nanocurie-scale quantities are generally below exempt limits for most isotopes, but universities and companies typically hold broad licenses covering all their work anyway. The license requirements are not about the activity alone — they are about accountability, training, waste disposal, and ensuring that small amounts do not accumulate into large ones through careless stockpiling.

For short-lived isotopes (half-life under 120 days), most institutions use "decay in storage" — the waste sits in a shielded cabinet for 10 half-lives until it is indistinguishable from background, then gets disposed of as normal chemical waste with all radioactive labels removed. For longer-lived isotopes like tritium (12.3-year half-life) or carbon-14 (5,730 years), the waste is collected in designated containers, catalogd by isotope and activity, and shipped to a licensed low-level radioactive waste broker. At nanocurie levels the volumes are small, so the main cost is paperwork, not shielding.

The patient swallows a capsule containing 1–7 GBq of I-131. The thyroid gland concentrates iodine from the bloodstream — it cannot tell radioactive iodine from stable iodine — so the isotope accumulates right where you want it. I-131 emits beta particles with a range of about 2 mm in tissue, which destroy thyroid cells from the inside while sparing nearby structures. The gamma rays it also emits are used for imaging to verify uptake. Within weeks the targeted tissue is dead, no scalpel required.

At 3–7 GBq, a freshly treated thyroid cancer patient is a walking radiation source. They emit gamma rays and excrete I-131 in sweat, saliva, and urine for days. Regulations typically require isolation until the retained activity drops below 1.1 GBq or the dose rate at 1 meter falls below 25 µSv/hr. That usually means 2–5 days of sleeping alone, using a dedicated bathroom, and avoiding prolonged close contact — especially with children and pregnant women, who are more radiation-sensitive.

Brachytherapy places a sealed radioactive source directly inside or next to a tumor — "brachy" is Greek for "short distance." High-dose-rate (HDR) sources of iridium-192 at 100–370 GBq deliver an intense, highly localized dose in minutes. The inverse-square law means tissue just centimeters away receives dramatically less radiation. This precision is why brachytherapy can treat cervical, prostate, and breast cancers with fewer side effects than external beam radiation alone.

Industrial radiography sources (1–20 GBq of Ir-192 or Se-75) live inside heavy shielded containers called "cameras" or "projectors" made of depleted uranium or tungsten. The source is only pushed out through a guide tube during an exposure, and the area is roped off with radiation monitors. Strict transport regulations, tamper-proof locks, and regular inventory audits apply. When sources decay below useful activity, they are returned to the manufacturer. The IAEA maintains a database of lost or orphaned sources — the ones that slip through the system occasionally cause severe accidents.

Diagnostic procedures use just enough activity to produce a readable image — typically 50–800 MBq (0.05–0.8 GBq). The goal is information, not tissue destruction. Therapeutic procedures aim to kill cells, so they use 10 to 100 times more: 1–7 GBq for thyroid ablation, 100–370 GBq for HDR brachytherapy sources. The line between them is roughly 1 GBq. Below that, you are taking a picture; above it, you are prescribing a lethal dose to a very specific target.